Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis

Core Evidence

Volumn 6, Issue , 2011, Pages 13-21

  Portaccio, Emilio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Fingolimod; FTY720; Multiple sclerosis; Oral treatment; S1P receptors

Indexed keywords

BETA1 INTERFERON; FINGOLIMOD;

ALLERGIC ENCEPHALOMYELITIS; APPENDICITIS; AREA UNDER THE CURVE; BASAL CELL CARCINOMA; BLOOD PRESSURE; BRADYCARDIA; BREAST CANCER; CANCER SURGERY; CHICKENPOX; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART RATE; HEART VENTRICLE TACHYCARDIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; JAUNDICE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; URINARY TRACT INFECTION;

EID: 80052756930     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S10101     Document Type: Review

References (56)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 1502-1517.
2. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707-717.
3. Lassmann H. Recent neuropathological findings in multiple sclerosis - implications for diagnosis and therapy. J Neurol. 2004;251 Suppl 4: IV2-IV5.
4. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol. 2008;255(10): 1449-1463.
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
7. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995; 45(7):1268-1276.
9. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71(10):766-773.
10. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-897.
11. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10): 903-914.
12. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470.
13. Mancardi GL, Amato MP, D'Alessandro R, et al. Natalizumab: A country-based surveillance program. Neurol Sci. 2008;29 Suppl 2: S235-S237.
14. Tedeschi G, Amato MP, D'Alessandro R, et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci. 2009;30 Suppl 2:S163-S165.
15. Mancardi GL, Tedeschi G, Amato MP, et al. Three years of experience: The Italian registry and safety data update. Neurol Sci. 2010 Jul 20. [Epub ahead of print].
16. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6): 453-462.
17. Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology. 2010;74 Suppl 1:S47-S53.
18. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):416-426.
19. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277(24):21453-21457.
20. Gilenya label and approval history. Available from: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist. Accessed 2010 Oct 8.
21. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994;47(2):208-215.
22. Spiegel S, Milstien S. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans. 2003;31(Pt 6):1216-1219.
23. Ishii I, Ye X, Friedman B, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem. 2002;277(28):25152-25159.
24. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84-105.
25. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360.
26. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296(5566):346-349.
27. Terai K, Soga T, Takahashi M, et al. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat central nervous system. Neuroscience. 2003;116(4):1053-1062.
28. Yu N, Lariosa-Willingham KD, Lin FF, Webb M, Rao TS. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia. 2004;45(1): 17-27.
29. Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459-1469.
30. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia. 2007; 55(16):1656-1667.
31. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005;2(6):439-448.
32. Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007; 74(5):307-316.
33. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
34. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5): 402-415.
35. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol Exp Ther. 2003;305(1):70-77.
36. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol. 2003;64(5):1199-1209.
37. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323(2):469-475.
38. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176(6):2682-2694.
39. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323(2): 26-635.
40. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 2007;21(7): 1503-1514.
41. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem. 2007;102(4):1151-1161.
42. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102(10):3665-3667.
43. Lan YY, de Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant. 2005;5(11):2649-2659.
44. Cinamon G, Zachariah MA, Lam OM, Foss FW Jr, Cyster JG. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol. 2008;9(1):54-62.
45. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 2003; 278(47):47281-47290.
46. Kim HJ, Jung CG, Dukala D, et al. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. J Neuroimmunol. 2009; 214(1-2):93-100.
47. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study. Transplantation. 2003;76(7):1079-1084.
48. Kovarik JM, Dole K, Riviere GJ, et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol. 2009;49(2):212-218.
49. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 200;44(5):532-537.
50. Graeler M, Shankar G, Goetzl EJ. Cutting edge: Suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol. 2002;169(8): 4084-4087.
51. Kabashima K, Haynes NM, Xu Y, et al. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med. 2006;203(12):2683-2690.
52. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004;57(5):586-591.
53. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008; 71(16):1261-1267.
54. Han S, Zhang X, Wang G, et al. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood. 2004;104(13): 4129-4133.
55. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
56. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology. 2010; 75(20):1794-1802.